Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 377Gynecologic 26Thoracic 19Gastrointestinal 14Genitourinary 12Tumor-Agnostic 10Other solid neoplasm 9Head & Neck 6Sarcoma 5Endocrine 4Lymphoid 3Other neoplasm 2Dermatologic 2CNS 2

Conditions

Breast Neoplasms 2Brain Neoplasms 2

Interventions

Temozolomide 610Radiotherapy 387Bevacizumab 253Magnetic Resonance Spectroscopy 202Cyclophosphamide 177Carboplatin 159Radiosurgery 145Etoposide 132Radiation 120Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 81Lomustine 80Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Fulvestrant × CNS × Clear all
NCT03803761 2023-09-25

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04334330 2022-05-02

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Sun Yat-sen University

Phase 2 Unknown
34 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡